These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

191 related items for PubMed ID: 27373274

  • 1. Structure and activation of pro-activin A.
    Wang X, Fischer G, Hyvönen M.
    Nat Commun; 2016 Jul 04; 7():12052. PubMed ID: 27373274
    [Abstract] [Full Text] [Related]

  • 2. Structure of the human myostatin precursor and determinants of growth factor latency.
    Cotton TR, Fischer G, Wang X, McCoy JC, Czepnik M, Thompson TB, Hyvönen M.
    EMBO J; 2018 Feb 01; 37(3):367-383. PubMed ID: 29330193
    [Abstract] [Full Text] [Related]

  • 3. Prodomain-growth factor swapping in the structure of pro-TGF-β1.
    Zhao B, Xu S, Dong X, Lu C, Springer TA.
    J Biol Chem; 2018 Feb 02; 293(5):1579-1589. PubMed ID: 29109152
    [Abstract] [Full Text] [Related]

  • 4. The structure of the follistatin:activin complex reveals antagonism of both type I and type II receptor binding.
    Thompson TB, Lerch TF, Cook RW, Woodruff TK, Jardetzky TS.
    Dev Cell; 2005 Oct 02; 9(4):535-43. PubMed ID: 16198295
    [Abstract] [Full Text] [Related]

  • 5. New insights into the mechanisms of activin action and inhibition.
    Walton KL, Makanji Y, Harrison CA.
    Mol Cell Endocrinol; 2012 Aug 15; 359(1-2):2-12. PubMed ID: 21763751
    [Abstract] [Full Text] [Related]

  • 6. Structures of an ActRIIB:activin A complex reveal a novel binding mode for TGF-beta ligand:receptor interactions.
    Thompson TB, Woodruff TK, Jardetzky TS.
    EMBO J; 2003 Apr 01; 22(7):1555-66. PubMed ID: 12660162
    [Abstract] [Full Text] [Related]

  • 7. The structure of FSTL3.activin A complex. Differential binding of N-terminal domains influences follistatin-type antagonist specificity.
    Stamler R, Keutmann HT, Sidis Y, Kattamuri C, Schneyer A, Thompson TB.
    J Biol Chem; 2008 Nov 21; 283(47):32831-8. PubMed ID: 18768470
    [Abstract] [Full Text] [Related]

  • 8. Structural basis for the inhibition of activin signalling by follistatin.
    Harrington AE, Morris-Triggs SA, Ruotolo BT, Robinson CV, Ohnuma S, Hyvönen M.
    EMBO J; 2006 Mar 08; 25(5):1035-45. PubMed ID: 16482217
    [Abstract] [Full Text] [Related]

  • 9. Rapid Activation of Bone Morphogenic Protein 9 by Receptor-mediated Displacement of Pro-domains.
    Kienast Y, Jucknischke U, Scheiblich S, Thier M, de Wouters M, Haas A, Lehmann C, Brand V, Bernicke D, Honold K, Lorenz S.
    J Biol Chem; 2016 Feb 12; 291(7):3395-410. PubMed ID: 26677222
    [Abstract] [Full Text] [Related]

  • 10. The role of follistatin domains in follistatin biological action.
    Keutmann HT, Schneyer AL, Sidis Y.
    Mol Endocrinol; 2004 Jan 12; 18(1):228-40. PubMed ID: 14563935
    [Abstract] [Full Text] [Related]

  • 11. Pluripotency gene expression and growth control in cultures of peripheral blood monocytes during their conversion into programmable cells of monocytic origin (PCMO): evidence for a regulatory role of autocrine activin and TGF-β.
    Ungefroren H, Hyder A, Hinz H, Groth S, Lange H, El-Sayed KM, Ehnert S, Nüssler AK, Fändrich F, Gieseler F.
    PLoS One; 2015 Jan 12; 10(2):e0118097. PubMed ID: 25707005
    [Abstract] [Full Text] [Related]

  • 12. Human and mouse activin genes: Divergent expression of activin A protein variants and identification of a novel heparan sulfate-binding domain in activin B.
    Billings PC, Bizzaro C, Yang E, Chung J, Mundy C, Pacifici M.
    PLoS One; 2020 Jan 12; 15(2):e0229254. PubMed ID: 32074129
    [Abstract] [Full Text] [Related]

  • 13. A molecular recognition paradigm: promiscuity associated with the ligand-receptor interactions of the activin members of the TGF-beta superfamily.
    Keah HH, Hearn MT.
    J Mol Recognit; 2005 Jan 12; 18(5):385-403. PubMed ID: 15948132
    [Abstract] [Full Text] [Related]

  • 14. Tolloid cleavage activates latent GDF8 by priming the pro-complex for dissociation.
    Le VQ, Iacob RE, Tian Y, McConaughy W, Jackson J, Su Y, Zhao B, Engen JR, Pirruccello-Straub M, Springer TA.
    EMBO J; 2018 Feb 01; 37(3):384-397. PubMed ID: 29343545
    [Abstract] [Full Text] [Related]

  • 15. Regulation and actions of Smad7 in the modulation of activin, inhibin, and transforming growth factor-beta signaling in anterior pituitary cells.
    Bilezikjian LM, Corrigan AZ, Blount AL, Chen Y, Vale WW.
    Endocrinology; 2001 Mar 01; 142(3):1065-72. PubMed ID: 11181520
    [Abstract] [Full Text] [Related]

  • 16. Imbalance between activin A and follistatin drives postburn hypertrophic scar formation in human skin.
    Fumagalli M, Musso T, Vermi W, Scutera S, Daniele R, Alotto D, Cambieri I, Ostorero A, Gentili F, Caposio P, Zucca M, Sozzani S, Stella M, Castagnoli C.
    Exp Dermatol; 2007 Jul 01; 16(7):600-10. PubMed ID: 17576240
    [Abstract] [Full Text] [Related]

  • 17. Latent TGF-β structure and activation.
    Shi M, Zhu J, Wang R, Chen X, Mi L, Walz T, Springer TA.
    Nature; 2011 Jun 15; 474(7351):343-9. PubMed ID: 21677751
    [Abstract] [Full Text] [Related]

  • 18. Structural and biophysical coupling of heparin and activin binding to follistatin isoform functions.
    Lerch TF, Shimasaki S, Woodruff TK, Jardetzky TS.
    J Biol Chem; 2007 May 25; 282(21):15930-9. PubMed ID: 17409095
    [Abstract] [Full Text] [Related]

  • 19. Regulation of brown adipogenesis by the Tgf-β family: involvement of Srebp1c in Tgf-β- and Activin-induced inhibition of adipogenesis.
    Yoshida H, Kanamori Y, Asano H, Hashimoto O, Murakami M, Kawada T, Matsui T, Funaba M.
    Biochim Biophys Acta; 2013 Nov 25; 1830(11):5027-35. PubMed ID: 23850470
    [Abstract] [Full Text] [Related]

  • 20. Differential Expression and Release of Activin A and Follistatin in Chronic Rhinosinusitis with and without Nasal Polyps.
    Yang Y, Zhang N, Crombruggen KV, Lan F, Hu G, Hong S, Bachert C.
    PLoS One; 2015 Nov 25; 10(6):e0128564. PubMed ID: 26030615
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.